A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Shanghai Jiatan Pharmatech Co., Ltd, now recruiting.
Overview
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06117566 by Shanghai Jiatan Pharmatech Co., Ltd, with 100 participants planned, started 2022-11-18 and due to reach its primary completion in 2025-11-09. Interventions recorded: WX390 and Toripalimab.
Similar pages
not linked directly; found by shared links- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Shares Toripalimab and the tag pipeline.
- TrialA Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
Shares Toripalimab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.